Intelligencia

Intelligencia, founded in 2017, provides AI-powered solutions to de-risk drug development and enhance decision-making. Headquartered in New York with additional offices in San Francisco and Athens, Greece, the company employs 110 individuals globally. Intelligencia offers SaaS products, including the Intelligencia Portfolio Optimizer and Clinical Development Insights, which specialize in data and insights for clinical development. The company received a U.S. patent for its accurate and transparent probability of drug success (PTRS) assessments, which measure the likelihood of success for drugs across multiple therapeutic areas. Intelligencia helps identify underlying drivers contributing to technical and regulatory risk in drug development, providing a single source of quality, harmonized data for consistent risk evaluation. The company’s solutions offer real-time tracking of clinical programs organized by proprietary ontologies and are trusted by leading pharmaceutical organizations for PTRS/PoS calculations. Intelligencia has achieved high prospective accuracy (>80%) in real-world predictions and provides state-of-the-art explainable AI and transparency into PTRS predictions. The company’s AI-powered solutions are built with comprehensive, precise data, focusing on de-risking clinical development with AI-driven probability of success assessments. Intelligencia helps organizations realize superior decision-making power for phase transition and PTRS predictions, providing data visualizations into the competitive landscape through Clinical Development Insights and using proprietary ontologies to systematically search and surface relevant clinical trial characteristics.